ADAG vs ABBV vs JPM vs MRK vs BMY

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -99. 4% for Adagene Inc. (ADAG). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Adagene Inc. (ADAG) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus AbbVie Inc. at 96. 1x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Merck & Co. , Inc. 's 1. 09x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +123. 7%, compared to -73. 7% for Adagene Inc. (ADAG). Over 10 years, the gap is even starker: JPM returned +465. 8% versus ADAG's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately 593% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Adagene Inc. (ADAG) carries a lower debt/equity ratio of 37% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -99. 4% for Adagene Inc. (ADAG). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -75. 9% for Adagene Inc.. Over a 3-year CAGR, MRK leads at 3. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -323. 9% for Adagene Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -348. 4% for ADAG. At the gross margin level — before operating expenses — MRK leads at 72. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Merck & Co. , Inc. 's 1. 09x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 9. 0x forward P/E versus 23. 2x for Merck & Co. , Inc. — 14. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADAG: 40. 1% to $5. 00.

In this comparison, BMY (4.

3% yield), ABBV (2. 9% yield), MRK (2. 7% yield), JPM (1. 9% yield) pay a dividend. ADAG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Both have compounded well over 10 years (ABBV: +362. 2%, ADAG: -88. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ADAG (Healthcare) and ABBV (Healthcare) and JPM (Financial Services) and MRK (Healthcare) and BMY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ADAG is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock; JPM is a large-cap deep-value stock; MRK is a large-cap deep-value stock; BMY is a mid-cap deep-value stock. ABBV, JPM, MRK, BMY pay a dividend while ADAG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.